Equities analysts expect that MediWound Ltd. (NASDAQ:MDWD) will post sales of $740,000.00 for the current quarter, according to Zacks. Three analysts have issued estimates for MediWound’s earnings, with the highest sales estimate coming in at $820,000.00 and the lowest estimate coming in at $600,000.00. MediWound posted sales of $520,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 42.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that MediWound will report full year sales of $740,000.00 for the current year, with estimates ranging from $2.50 million to $3.40 million. For the next year, analysts anticipate that the business will post sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover MediWound.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The firm’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.34) EPS.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of MediWound from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Jefferies Group LLC set a $10.00 price objective on shares of MediWound and gave the company a “buy” rating in a research note on Friday, August 25th. Oppenheimer Holdings, Inc. set a $10.00 price objective on shares of MediWound and gave the company a “buy” rating in a research note on Monday, May 8th. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Finally, Aegis reissued a “buy” rating and issued a $11.00 price objective on shares of MediWound in a research note on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $9.19.

Shares of MediWound (NASDAQ:MDWD) traded up 1.0887% during mid-day trading on Wednesday, reaching $6.2675. 3,428 shares of the company’s stock traded hands. MediWound has a 12-month low of $4.25 and a 12-month high of $8.58. The company’s market cap is $137.60 million. The company’s 50 day moving average is $6.66 and its 200 day moving average is $6.52.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/30/mediwound-ltd-mdwd-expected-to-announce-quarterly-sales-of-740000-00.html.

Several large investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC boosted its stake in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN boosted its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. 23.47% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.